DeLong Mark Jeffrey 4
4 · Apellis Pharmaceuticals, Inc. · Filed Feb 12, 2025
Insider Transaction Report
Form 4
DeLong Mark Jeffrey
Chief Business & Strat Officer
Transactions
- Sale
Common Stock
2025-02-11$28.54/sh−363$10,360→ 83,945 total
Footnotes (1)
- [F1]This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 10, 2025